Moleculin Biotech
MBRX
6 hedge funds and large institutions have $326K invested in Moleculin Biotech in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IG
ING Group
Amsterdam,
Netherlands
|
+$146K |
| 2 |
SIM
Spark Investment Management
New York
|
+$129K |
| 3 |
Citigroup
New York
|
+$32.3K |
| 4 |
Barclays
London,
United Kingdom
|
+$16.2K |
| 5 |
Morgan Stanley
New York
|
+$16.2K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IG
1
ING Group
Amsterdam,
Netherlands
| $132K | +$146K | +9 | New |
|
|
SIM
2
Spark Investment Management
New York
| $124K | +$129K | +8 | New |
|
|
3
Citigroup
New York
| $33K | +$32.3K | +2 | New |
|
|
4
Barclays
London,
United Kingdom
| $9K | +$16.2K | +1 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $9K | +$16.2K | +1 | New |
|
6
UBS Group
Zurich,
Switzerland
| $8K | – | – | – |
|
|
7
Morgan Stanley
New York
| $8K | +$16.2K | +1 | New |
|
|
NFG
8
Next Financial Group
Houston,
Texas
| $3K | – | – | – |
|
MBRX Hedge Fund Activity: Q2 2016 in Review
6 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2016, worth a combined $326K.
Buyers outnumbered sellers: 6 funds opened new MBRX positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was ING Group, opening a new position worth an estimated $146K.
- 6 institutional investors held Moleculin Biotech (MBRX) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $326K of Moleculin Biotech stock for Q2 2016.
- 6 funds opened new Moleculin Biotech positions in Q2 2016 and 0 closed out, a net change of +6 holders.
- The largest Moleculin Biotech buyer in Q2 2016 was ING Group, an estimated $146K added.
Based on aggregated 13F filings for Q2 2016.